ProVee System for BPH
Proverum, Ltd. · Decision date Mar 19, 2026
What did the FDA approve?
FDA records P250011/S001 as a supplement to PMA P250011, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Mar 19, 2026.
FDA approval order statement
a revised precaution statement recommending use of a straight catheter in patients with the ProVee implant who need catheterization
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Mar 19, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P250011/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Proverum, Ltd.
- Product code
- MER
- Decision code
- APPR
- Decision date
- Mar 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT.
- Applicant
- Proverum, Ltd.
- Product code
- MER
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250011 · Original PMA
ProVee System for BPH
P250011/S001 received
Application receipt date recorded by FDA.
P250011/S001 · FDA decision
Special (Immediate Track)
P250011/S002 · Related supplement
ProVee System for BPH
P250011/S003 · Related supplement
ProVee System for BPH
P250011/S004 · Related supplement
ProVee System for BPH
P250011/S006 · Related supplement
ProVee System for BPH
P250011/S005 · Related supplement
ProVee System for BPH
Timeline entries are records held by MedtechLedger for P250011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProVee System for BPHP250011 | Proverum, Ltd. | PMA approval | Dec 9, 2025 | FDA |
ProVee System for BPHP250011/S002 | Proverum, Ltd. | PMA supplement | Jun 3, 2026 | FDA |
ProVee System for BPHP250011/S003 | Proverum, Ltd. | PMA supplement | Jun 15, 2026 | FDA |
ProVee System for BPHP250011/S004 | Proverum, Ltd. | PMA supplement | Jul 1, 2026 | FDA |
ProVee System for BPHP250011/S006 | Proverum, Ltd. | PMA supplement | Sep 24, 2026 | FDA |
ProVee System for BPHP250011/S005 | Proverum, Ltd. | PMA supplement | Nov 3, 2026 | FDA |
Explore the linked device profile
Other records with product code MER
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Zenflow, Inc. | PMA approval | Dec 11, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Proverum, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2nd Floor Astor Hall, 4-8 Eden Quay, Dublin, D01N5W8
Sources and methodology
- Original FDA record: P250011/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




